Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database
The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background and Aims: Although relatively, primary biliary cholangitis (PBC) is an important cause of nonalcoholic chronic liver disease which may lead to liver transplantation. PBC patients with alkaline phosphatase (ALP) ≥1.5× the upper limit of normal (ULN) tend to have a more aggressive course. The study was designed to identify factors associated with ALP≥1.5×ULN or cirrhosis in PBC and to evaluate concomitant health care resource utilization. Methods: We used a large real-world database that contained comprehensive and continuous electronic medical recored/claims data from over 500 health care practices or systems from the United States. Results: Of 195 million patients included in the database, 36,317 were adults with PBC. After applying exclusion criteria, 15,875 patients comprised the final PBC cohort (63.0±13.5 y, 78% female, 71% privately insured, 5% covered by Medicaid, 57% with other autoimmune diseases, 46% with cirrhosis); 6083 (38%) had ALP≥1.5×ULN. Patients with ALP≥1.5×ULN were more frequently female, less covered by Medicaid, had more pruritus, cirrhosis, and other autoimmune diseases (P<0.05). In multivariate analysis, older age, female gender, the presence of other autoimmune diseases, and having compensated or decompensated cirrhosis were independently associated with having ALP≥1.5×ULN in PBC (P<0.05). In contrast, being male was associated with higher risk of cirrhosis in PBC [odds ratio 2.3 (95% confidence interval, 2.1-2.5)]. Patients with ALP≥1.5×ULN and/or with cirrhosis also incurred substantially more health care resource utilization (P<0.05). Conclusions: Many clinical, sociodemographic, and economic factors are associated with a potentially more aggressive profile of PBC with elevated ALP. These data may inform clinicians to implement management strategies to optimize care of these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“approximately 40% of UDCA-treated patients still go on to develop cirrhosis (40% in a multicentre study of >1000 patients over 10 years14; 46% of patients in contemporary USA ‘real world data’ report of 15 875 patients,15”
Citations
Cites
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Corpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Selmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Extrahepatic autoimmune conditions associated with primary biliary cirrhosis
Floreani, A., Franceschet, I., Cazzagon, N., Spinazzè, A., Buja, A., Furlan, P., Baldo, V., & Gershwin, M. E. (2015) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8427-x · Cited by 188
Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review
Sorokin, A., Brown, J. L., & Thompson, P. D. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.036 · Cited by 167
Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study
Boonstra, K., Kunst, A. E., Stadhouders, P. H., Tuynman, H. A., Poen, A. C., van Nieuwkerk, K. M. J., Witteman, E. M., Hamann, D., Witteman, B. J., Beuers, U., et al. (2014) · Liver International · doi:10.1111/liv.12434 · Cited by 112
Optimal timing of liver transplantation for primary biliary cirrhosis
Kim, R. W., Wiesner, R. H., Therneau, T. M., Poterucha, J. J., Porayko, M. K., Evans, R. W., Klintmalm, G. B., Crippin, J. S., Krom, R. A., & Dickson, R. E. (1998) · Hepatology · doi:10.1002/hep.510280106 · Cited by 100
Cited by
Kowdley, K. V., Hirschfield, G. M., Coombs, C., Malecha, E. S., Bessonova, L., Li, J., Rathnayaka, N. S., Mells, G. F., Jones, D. E., Trivedi, P. J., et al. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003029 · Cited by 80
Cortez‐Pinto, H., Liberal, R., Lopes, S., Machado, M. V., Carvalho, J., Dias, T., Santos, A., Agostinho, C., Figueiredo, P., Loureiro, R., et al. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12095 · Cited by 53
“This becomes particularly important, since there are now available second line treatments, such as obeticholic acid, fibrates and budesonide.(5,7) Therefore, identifying patients at higher risk of incomplete biochemical response to UDCA treatment at diagnosis may be useful 700 UNITED EUROPEAN GASTROENTEROLOGY JOURNAL”
BackgroundA Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases
Younossi, Z. M., Golabi, P., & Henry, L. L. (2019) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001179 · Cited by 50
Self-citationGender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice
Invernizzi, F., Cilla, M., Trapani, S., Guarino, M., Cossiga, V., Gambato, M., Morelli, M. C., Morisco, F., Burra, P., & Floreani, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060925 · Cited by 45
“In general, LT in this setting has a favorable overall outcome, with current patient and graft survival for all indications in Europe ranging from 64 to 80% at 5 years, depending on the indication (HCC or not), etiology and severity of the disease [51,112,119].”
BackgroundInfluentialEpidemiological and economical burden of cholestatic liver disease
Mol, B., Werner, E., Culver, E. L., van der Meer, A. J., Bogaards, J. A., & Ponsioen, C. Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001341 · Cited by 31
Metadata
- Authors
- Younossi, Z. M., Stepanova, M., Golabi, P., Epstein, R. S., Strauss, M. E., Nader, F., & Racila, A.
- Affiliations
- Inova Health System (US)
- Center for Outcomes Research in Liver Diseases (US)
- Epstein Health, LLC, Woodcliff Lake, NJ
- Intercept Pharmaceuticals (United States) (US)
- Corresponding author
- Younossi, Zobair M.
- Racila, Andrei
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2019-10
- Volume
- 53
- Issue
- 9
- Pages
- 693-698
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2888641739
- Cited by
- 18
- References
- 28
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 1 · 2019: 2
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, alkaline phosphatase elevation, liver cirrhosis, disease progression, healthcare resource utilization, pruritus, autoimmune disease comorbidity, sex differences, Medicaid
- MeSH terms
- Age Factors, Aged, Alkaline Phosphatase, Autoimmune Diseases, Female, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Risk Factors, Sex Factors, Socioeconomic Factors, United States, Cohort Studies, Databases, Factual, Disease Progression, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database. https://app.cochat.ai/papers/10.1097/mcg.0000000000001120
- The paper
- Younossi, Z. M., Stepanova, M., Golabi, P., Epstein, R. S., Strauss, M. E., Nader, F., & Racila, A. (2019). Factors Associated With Potential Progressive Course of Primary Biliary Cholangitis: Data From Real-world US Database. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0000000000001120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.